SEC Tracker
Get the app

Niki BioSolutions NIKI

Niki BioSolutions FY 2023: revenue $431K, down 67%; diluted EPS −$0.62

Form
20-F
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Niki BioSolutions reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$431K−67% from $1.3M in FY 202220-F income statement, on EDGAR
  2. Net income−$2.8MAgainst −$11.5M in FY 202220-F income statement, on EDGAR
  3. Diluted EPS−$0.62Against −$2.75 in FY 202220-F income statement, on EDGAR
  4. Cash and cash equivalents$2.0M−60% from $5.0M in FY 202220-F balance sheet, on EDGAR
  5. Cash from operations−$7.7MAgainst −$12.3M in FY 202220-F cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Niki BioSolutions files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3829 and related industry codes: the same peer list as the financial tables.

  1. Autoscope Technologies AATC
  2. Birchtech BCHT public float $51M, Jun 30, 2025
  3. Flexpoint Sensor Systems FLXT
  4. Geospace Technologies GEOS public float $90M, Mar 31, 2025, over 18 months old
  5. Mirion Technologies MIR public float $4.8B, Jun 30, 2025